کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
8647279 | 1570193 | 2018 | 9 صفحه PDF | دانلود رایگان |
عنوان انگلیسی مقاله ISI
Natalizumab treatment shows low cumulative probabilities of confirmed disability worsening to EDSS milestones in the long-term setting
دانلود مقاله + سفارش ترجمه
دانلود مقاله ISI انگلیسی
رایگان برای ایرانیان
کلمات کلیدی
DMTEDSSRRMscumulative probabilitySPMSTOP - بالاDisease-modifying therapy - درمانی درمان بیماریExpanded Disability Status Scale - مقیاس وضعیت ناتوانی گسترش یافتهsecondary progressive multiple sclerosis - مولتیپل اسکلروز ثانویه پیشرفتهrelapsing-remitting multiple sclerosis - مولتیپل اسکلروزیس مجدد مجددNatalizumab - ناتالیزوماب
موضوعات مرتبط
علوم زیستی و بیوفناوری
بیوشیمی، ژنتیک و زیست شناسی مولکولی
ژنتیک
پیش نمایش صفحه اول مقاله

چکیده انگلیسی
In TOP patients with a median (range) baseline EDSS score of 3.5 (0.0-9.5) who completed 24 months of natalizumab treatment, the rate of 48-week confirmed disability worsening events was below 15%; after approximately 5.5 years of natalizumab treatment, 86.5% and 94.7% of patients did not have EDSS score increases of â¥1.0 or â¥2.0 points, respectively. The presence of relapses was associated with higher rates of overall disability worsening. These results were confirmed by assessing transition to EDSS milestones. Lower rates of overall 48-week confirmed EDSS worsening and of transitioning from EDSS score 4.0-5.0 to â¥6.0 in the absence of relapses suggest that relapses remain a significant driver of disability worsening and that on-treatment relapses in natalizumab-treated patients are of prognostic importance.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Multiple Sclerosis and Related Disorders - Volume 24, August 2018, Pages 11-19
Journal: Multiple Sclerosis and Related Disorders - Volume 24, August 2018, Pages 11-19
نویسندگان
Maria Trojano, Helmut Butzkueven, Ludwig Kappos, Heinz Wiendl, Tim Spelman, Fabio Pellegrini, Yi Chen, Qunming Dong, Harold Koendgen, Shibeshih Belachew,